NDATOPICALCREAM
Approved
Aug 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
FLUOROPLEX (fluorouracil) by Molecular Devices is (dna) and to a lesser extent inhibits the formation of ribonucleic acid (rna); these affect rapidly growing cells and may lead to cell death. First approved in 1971.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUOROPLEX is a topical cream formulation of fluorouracil, a nucleoside analog that inhibits DNA and RNA synthesis in rapidly dividing cells, leading to cell death. It is primarily used for treatment of actinic keratosis and other dermatological malignancies. The drug's active metabolites interfere with thymidylate synthase and incorporate into both DNA and RNA, making it effective against fast-growing skin lesions.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting defensive positioning and potential team restructuring as LOE approaches.
Mechanism of Action
(DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′triphosphate (FUTP) and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Started Apr 2026
900 enrolled
Metastatic Pancreatic Ductal AdenocarcinomaPDAC
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Started Apr 2026
90 enrolled
Esophageal Squamous Cell Carcinoma
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Started Jan 2026
50 enrolled
Metastatic Colorectal Cancer (CRC)
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Started Sep 2025
0Metastatic Colorectal Cancer
Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo
Started Aug 2025
40 enrolled
Vitiligo
Worked on FLUOROPLEX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.